Travelers Diarrhea - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Traveler's Diarrhea - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Traveler's Diarrhea - Pipeline Review, H1 2015’, provides an overview of the Traveler's Diarrhea’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Traveler's Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traveler's Diarrhea and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Traveler's Diarrhea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Traveler's Diarrhea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Traveler's Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Traveler's Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Traveler's Diarrhea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Traveler's Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Traveler's Diarrhea Overview 7
Therapeutics Development 8
Pipeline Products for Traveler's Diarrhea - Overview 8
Pipeline Products for Traveler's Diarrhea - Comparative Analysis 9
Traveler's Diarrhea - Therapeutics under Development by Companies 10
Traveler's Diarrhea - Therapeutics under Investigation by Universities/Institutes 11
Traveler's Diarrhea - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Traveler's Diarrhea - Products under Development by Companies 15
Traveler's Diarrhea - Products under Investigation by Universities/Institutes 16
Traveler's Diarrhea - Companies Involved in Therapeutics Development 17
Chiesi Farmaceutici SpA 17
Cosmo Pharmaceuticals S.p.A 18
GlycoVaxyn AG 19
Nippon Shinyaku Co., Ltd. 20
Prokarium Ltd. 21
Scandinavian Biopharma Holding AB 22
Sigmoid Pharma Limited 23
Traveler's Diarrhea - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ACE-527 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ACE-920 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Etvax - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GVXNSD-133 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Helicobacter pylori [Hel-305] (multivalent) vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
INX-201 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
prulifloxacin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rifamycin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Typhetec - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Traveler's Diarrhea - Recent Pipeline Updates 47
Traveler's Diarrhea - Discontinued Products 50
Traveler's Diarrhea - Product Development Milestones 51
Featured News & Press Releases 51
Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea 51
Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea 52
Aug 17, 2011: TD Vaccines To Present ACE527 Phase II Data At Sachs 11th Annual Biotech In Europe 53
Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 53
Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting 54
Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria 55
Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers 55
Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting 56
Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial 57
Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Traveler's Diarrhea, H1 2015 8
Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Traveler's Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H1 2015 17
Traveler's Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 18
Traveler's Diarrhea - Pipeline by GlycoVaxyn AG, H1 2015 19
Traveler's Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 20
Traveler's Diarrhea - Pipeline by Prokarium Ltd., H1 2015 21
Traveler's Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2015 22
Traveler's Diarrhea - Pipeline by Sigmoid Pharma Limited, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Traveler's Diarrhea Therapeutics - Recent Pipeline Updates, H1 2015 47
Traveler's Diarrhea - Discontinued Products, H1 2015 50